Skip to main content

PharmaCyte Biotech, Inc.

PMCB
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001157075

No open-market purchases or sales by PharmaCyte Biotech, Inc. insiders were filed in the last 90 days; 32 institutions reported holding it in 13F filings for Q2 2026, worth $586.2K in total; no superinvestor holds it.

Q4 2023 vs. Q3 2023

How the institutions holding PharmaCyte Biotech, Inc. changed between Q3 2023 and Q4 2023.

All holders in Q4 2023All holders in Q3 2023

13F holders of PMCB: Q3 2023 compared with Q4 2023
MeasureQ3 2023Of which not filed for Q4 2023Q4 2023Change
Holders34136+3
Shares1.14M92.1K1.09M+37.5K (+3.6%)
Value$2.40M$193.4K$2.35M+$141.4K (+6.4%)

1 institution that held it in Q3 2023 haven't filed for Q4 2023 yet. Not filing isn't selling, so the changes leave them out.

New holders (5)

Institutions that held PharmaCyte Biotech, Inc. at the end of Q4 2023 but not at the end of Q3 2023.

Institutions new to PMCB in Q4 2023
InstitutionSharesValue% of portfolio
Susquehanna International Group, LLP22,028$47.6K0.00%
Squarepoint Ops LLC14,846$32.1K0.00%
Private Wealth Management Group, LLC42$910.00%
Sachetta, LLC14$310.00%
Northwestern Mutual Wealth Management Co14$300.00%

Sold out (2)

Institutions that held PharmaCyte Biotech, Inc. at the end of Q3 2023 and filed for Q4 2023 without it.

Institutions that sold out of PMCB in Q4 2023
InstitutionShares, Q3 2023Value, Q3 2023
CSS LLC13,186$27.7K
Simplex Trading, LLC199$0

Not filed for Q4 2023 yet (1)

Institutions that held PharmaCyte Biotech, Inc. at the end of Q3 2023 and haven't filed a 13F for Q4 2023. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding PMCB in Q3 2023 that haven't filed for Q4 2023
InstitutionShares, Q3 2023Value, Q3 2023
Ayrton Capital LLC92,087$193.4K